Skip to content

DraconiticBiochemistryBiomolecules · Catabolism · Biosynthesis · MetabolismMap

Data

Loading the map…

Human metabolism

Reactome's human metabolism drawn as one network. Each molecule has one home node; widely shared molecules also appear as dashed copies in other territories, linked from their details. .

Territories

Select a territory to bring it forward.

Reading the map

Metabolite; its structure appears as you zoom in
Reaction, arrow toward the product
Cofactors and co-substrates are written beside the reaction when you zoom in
Dashed ring: a copy of a widely shared molecule or cofactor in another territory or pathway
Compartment transfer of the molecule it is linked to
Binding, release or complex event; its proteins are named in its details
Outline: reactions mostly in the mitochondrion

Arrows follow Reactome's curated reaction direction.

SRD5A2 binds SRD5A2 inhibitors

SRD5A2 + SRD5A2 inhibitors → SRD5A2:SRD5A2 inhibitors

Reactome: R-HSA-9705794
Compartment: cytosol · endoplasmic reticulum membrane
Rhea: None recorded

Inputs

SRD5A2R-HSA-469664, endoplasmic reticulum membrane
SRD5A2 inhibitorsR-ALL-9705798, cytosol

Outputs

SRD5A2:SRD5A2 inhibitorsR-HSA-9705766, endoplasmic reticulum membrane

Literature

Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding J Med Chem, 1986
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride Clin Pharmacol Ther, 1998
Therapeutic options in the treatment of benign prostatic hyperplasia Patient Prefer Adherence, 2009
Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride Horm Mol Biol Clin Investig, 2010
Dutasteride: a review of its use in the management of prostate disorders Drugs, 2008
Finasteride for benign prostatic hyperplasia Am Fam Physician, 1992